Patient Education

Genzyme provides a variety of materials for healthcare professionals to help keep patients compliant with treatment regimens and educate them about topics such as dialysis, diet, and the use of phosphate binders. InBalance^™– an award winning comprehensive compliance, education, and motivation program – includes posters, brochures, and other materials.

Be sure to keep checking this web site as new educational materials will soon be available.

Patients interested in learning more about the InBalance educational materials should speak with a member of their dialysis care team.

Healthcare professionals interested in learning more about the InBalance educational materials should call Genzyme toll-free at 1-800-847-0069 or speak with their local Genzyme Clinical Science Specialist or Regional Clinical Consultant.

Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction.
Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery.
Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation.
Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction.
Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel.
Patients should be informed to take Renagel with meals and to adhere to their prescribed diets.

Please see accompanying full Prescribing Information.



	Terms and Conditions of Use \| Privacy Policy \| This site is intended for United States residents only. RG1061v2 © 2012 Genzyme Corporation. All rights reserved. Renagel and Genzyme are registered trademarks of Genzyme Corporation